1. Home
  2. URG vs PRTC Comparison

URG vs PRTC Comparison

Compare URG & PRTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ur Energy Inc (Canada)

URG

Ur Energy Inc (Canada)

HOLD

Current Price

$1.25

Market Cap

477.8M

ML Signal

HOLD

Logo PureTech Health plc

PRTC

PureTech Health plc

HOLD

Current Price

$16.91

Market Cap

386.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
URG
PRTC
Founded
2004
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
477.8M
386.7M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
URG
PRTC
Price
$1.25
$16.91
Analyst Decision
Strong Buy
Analyst Count
5
0
Target Price
$2.52
N/A
AVG Volume (30 Days)
9.9M
5.0K
Earning Date
11-03-2025
08-28-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
0.20
Revenue
$39,411,000.00
$6,391,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$183.54
N/A
P/E Ratio
N/A
$7.83
Revenue Growth
138.94
1265.60
52 Week Low
$0.55
$13.30
52 Week High
$2.35
$23.35

Technical Indicators

Market Signals
Indicator
URG
PRTC
Relative Strength Index (RSI) 41.24 51.09
Support Level $1.17 $16.44
Resistance Level $1.46 $17.17
Average True Range (ATR) 0.07 0.35
MACD 0.01 0.12
Stochastic Oscillator 27.62 55.29

Price Performance

Historical Comparison
URG
PRTC

About URG Ur Energy Inc (Canada)

Ur-Energy Inc is engaged in uranium mining and recovery operations, with activities including the acquisition, exploration, development, and production of uranium mineral resources located in Wyoming. The company owns and operates the Lost Creek in-situ recovery uranium facility in south-central Wyoming, Lost Creek received an amendment to its license allowing the expansion of mining activities within the existing Lost Creek Project and the adjacent LC East Project.

About PRTC PureTech Health plc

PureTech Health PLC, together with its subsidiaries, is a clinical-stage biopharma company developing medicines to modulate the adaptive human system. The company is focused on developing and commercializing differentiated medicines for devastating diseases, including inflammatory, immunological conditions, intractable cancers, lymphatic & gastrointestinal diseases, and neurological and neuropsychological disorders, among others. Its drug development pipeline consists of Deupirfenidone (LYT-100), for the potential treatment of idiopathic pulmonary fibrosis (IPF), LYT-200, SPT-300, an oral drug for depressive disorder, SPT-320, and others. The company's operating segments include Parent Companies & Other, which derives key revenue, Wholly-Owned Programs, and Controlled Founded Entities.

Share on Social Networks: